AMBIEN CR
Pronunciation: ZOL-pi-dem (AM-bee-un)


What it isControlled-release GABA-A positive modulator; insomnia involving sleep onset and maintenance.
Why this oneIts biphasic tablet (outer layer for onset, core for maintenance) is labeled for sleep-maintenance insomnia, unlike IR.
What limits itBoxed complex sleep behaviors can occur after any exposure; next-day impairment, falls, and dependence also matter.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Short-term treatment of insomnia (sleep onset and/or maintenance) | Adults | 6.25 mg QHS (women); 6.25 or 12.5 mg QHS (men) | 12.5 mg QD | |
| Short-term treatment of insomnia | Geriatric/debilitated or mild–moderate hepatic impairment | 6.25 mg QHS | 6.25 mg QD |
Renal Undefined
Hepatic Mild–moderate: 6.25 mg QHS. Avoid in severe hepatic impairment (may precipitate encephalopathy).
Single dose per night; do not readminister during the same night
Available strengths
Pregnancy Late third-trimester use may cause neonatal respiratory depression and sedation.
Lactation May pump and discard breast milk during treatment and for 23 h after a dose.
| Strength | #/mo | generic $/mo | CostPlus | |
|---|---|---|---|---|
| 6.25 mg | ER tab | 30 qd | $3.05 | not offered |
| 12.5 mg | ER tab | 30 qd | $3.28 | not offered |
Other forms: Zolpidem (AMBIEN) · Zolpidem SL (EDLUAR)
⚠ BOXED WARNING
Legacy pregnancy categoryC
Defining liabilityComplex sleep behaviors, next-day impairment, falls and additive CNS depression.
Open Zolpidem CR in the interactive console ↗
